Annual report pursuant to Section 13 and 15(d)

SHAREHOLDERS' (DEFICIT) EQUITY - Additional Information (Details)

v3.24.1.u1
SHAREHOLDERS' (DEFICIT) EQUITY - Additional Information (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Aug. 16, 2023
Aug. 31, 2023
shares
Jun. 30, 2023
shares
May 31, 2023
USD ($)
$ / shares
shares
Mar. 31, 2023
USD ($)
$ / shares
shares
Aug. 31, 2022
USD ($)
$ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Sep. 30, 2022
shares
Jun. 09, 2021
$ / shares
shares
Apr. 30, 2020
$ / shares
SHAREHOLDERS' EQUITY (DEFICIT)                      
Common stock, shares authorized         9,000,000   9,000,000 9,000,000 180,000,000    
Common stock, par value (in dollars per share) | $ / shares         $ 0.001   $ 0.001 $ 0.001      
Common stock, shares issued             6,720,460 1,051,098      
Common stock, shares outstanding             6,720,460 1,051,098      
Period to submit plan to regain compliance 45 days                    
Proceeds from share issuance, net of share issuance costs | $             $ 5,383 $ 5,195      
Price per share | $ / shares       $ 1.20              
Pre-funded warrants       750,000              
Pre-funded warrants, shares   750,000                  
Warrant exercise price (in dollars per share) | $ / shares                   $ 1.20 $ 100.00
General corporate purposes, including working capital, marketing, and capital expenditures | $             5,100        
Common shares to certain employees, directors and vendors in lieu of cash compensation     59,748                
Reverse stock split ratio         0.05            
Fractional shares issued         0            
Gross proceeds | $             $ 5,383 $ 5,195      
Common share purchase warrants per unit                   1  
Number of Warrants Issued             750,000        
Number of Warrants Exercised             (750,000)        
Amended Stock Option Plan                      
SHAREHOLDERS' EQUITY (DEFICIT)                      
Common stock, shares outstanding             24,925        
Equity Incentive Plan                      
SHAREHOLDERS' EQUITY (DEFICIT)                      
Common stock, shares outstanding             11,500        
Number of shares authorized             88,500        
Private Placements                      
SHAREHOLDERS' EQUITY (DEFICIT)                      
Shares issued         50,000            
Shares issue price | $ / shares         $ 6.00            
Gross proceeds | $         $ 300            
Public offering (pre-funded warrants)                      
SHAREHOLDERS' EQUITY (DEFICIT)                      
Shares issued       5,000,000              
Price per share | $ / shares       $ 1.199              
Warrant exercise price (in dollars per share) | $ / shares       $ 0.001              
Gross proceeds | $       $ 6,000              
Option to purchase additional shares                      
SHAREHOLDERS' EQUITY (DEFICIT)                      
Shares issued       750,000              
Number of days to purchase additional shares       45 days              
Additional shares issued under allotment       0              
2022 Equity Financing                      
SHAREHOLDERS' EQUITY (DEFICIT)                      
Proceeds from share issuance, net of share issuance costs | $           $ 6,200          
Shares issued           278,804          
Period to purchase additional shares           45 days          
Percentage of additional shares issued           15.00%          
Shares issue price | $ / shares           $ 22.40          
Acquisition of Certain Assets of Innovation Neuromonitoring, LLC                      
SHAREHOLDERS' EQUITY (DEFICIT)                      
Share issuance, acquisition related (in shares)   547,946